Information For Healthcare Professionals
- Bavarian Nordic, manufacturer of JYNNEOS, has told the U.S. government it plans to put the vaccine on the commercial market around April 1, 2024.
- Federal agencies are working with Bavarian Nordic to ensure that people will continue to have broad access to this vaccine, including people who are uninsured and underinsured. HHS Mpox Vaccine Operational Planning Guide
- Mpox vaccination webpages are being updated to reflect commercialization of JYNNEOS.
NewNotice: Mpox illness, including severe infections, continue to occur across the United States. CDC urges clinicians to consider mpox when lesions consistent with mpox are observed in a patient, even if an alternate etiology (e.g., herpes simplex virus, syphilis) is considered more likely. Consult public health authorities for access to mpox therapeutics when appropriate. Treatment with tecovirimat can be considered via the NIH sponsored STOMP trial. Tecovirimat use under the expanded access Investigational New Drug protocol must be for patients who meet eligibility criteria and per the recommended dosing.
For persons with sexual risk factors for mpox who have not been diagnosed with mpox during the ongoing outbreak or have not already received 2 doses of the vaccine, CDC asks that clinicians encourage vaccination. Administration of additional vaccine doses is currently not recommended for any population and may not be legally covered if administered.
CDC urges healthcare providers in the U.S. to be alert for patients who have rash illnesses consistent with mpox.
Clinical RecognitionWhen properly administered before an exposure, vaccines are effective at protecting people against mpox.